On June 20, 2023, the U.S. Food and Drug Administration (FDA) expanded the approved age range for Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochloride), two medications used in the treatment of type 2 diabetes, to include patients as young as 10. These oral medications belong to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors that remove excess glucose from the blood by enhancing its excretion in the urine. Both medications were previously approved to treat type 2 diabetes in adult patients, as well as to reduce the risk of cardiovascular death and hospitalization in patients with cardiovascular disease or heart failure. In a study of patients ages 10-17 with type 2 diabetes, empagliflozin showed a greater reduction in hemoglobin A1C and fasting blood sugar compared to placebo. Increased risk of low blood sugar was the most common side effect reported throughout this trial. In the United States, there has been a steady increase in the rate of cases of pediatric patients with type 2 diabetes. Based on the current trend, it is estimated that there could be up to 220,000 cases by 2060. This expanded age range approval is very important in increasing the number or treatment options for pediatric patients with type 2 diabetes. Previously, metformin and insulin were the only approved treatment options for children.